Universal Beteiligungs und Servicegesellschaft mbH Acquires Shares of 35,393 Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 35,393 shares of the company's stock, valued at approximately $1,818,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.08% of Tarsus Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new position in Tarsus Pharmaceuticals during the fourth quarter worth about $44,000. Amalgamated Bank boosted its position in Tarsus Pharmaceuticals by 30.1% during the first quarter. Amalgamated Bank now owns 1,274 shares of the company's stock worth $65,000 after purchasing an additional 295 shares during the period. Quarry LP bought a new position in Tarsus Pharmaceuticals during the fourth quarter worth about $166,000. HighTower Advisors LLC bought a new position in Tarsus Pharmaceuticals during the fourth quarter worth about $207,000. Finally, Summit Investment Advisors Inc. boosted its position in Tarsus Pharmaceuticals by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock worth $213,000 after purchasing an additional 244 shares during the period. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Trading Up 5.1%

Shares of Tarsus Pharmaceuticals stock traded up $1.99 on Friday, hitting $40.81. The stock had a trading volume of 1,062,693 shares, compared to its average volume of 539,113. The company has a quick ratio of 5.54, a current ratio of 5.57 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals, Inc. has a one year low of $20.08 and a one year high of $57.28. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of -14.95 and a beta of 0.79. The stock's 50-day simple moving average is $41.40 and its two-hundred day simple moving average is $45.79.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative net margin of 44.91% and a negative return on equity of 39.72%. The firm had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. As a group, sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Oppenheimer assumed coverage on shares of Tarsus Pharmaceuticals in a report on Monday, June 2nd. They issued an "outperform" rating and a $75.00 price target on the stock. The Goldman Sachs Group raised their target price on shares of Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a research note on Monday, May 5th. Guggenheim raised their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. HC Wainwright raised shares of Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price on the stock in a research note on Tuesday, May 27th. Finally, Wall Street Zen downgraded shares of Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 22nd. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, Tarsus Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $66.67.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.